Abstract:Colorectal cancer (CRC) patients with BRAF mutations develop resistance to BRAF inhibitors at very early stage. Understanding the mechanisms involved in resistance to BRAF inhibitors is required to develop novel therapeutic opportunities for this subtype of CRC patients.
CRC cells bearing BRAF mutations are mostly sensitive to the abrogation of MKK3, a specific activator of p38MAPKs signaling, suggesting that BRAF alterations might addict CRC cells to the MKK3/p38MAPK signaling. Interestingly, publicly availab… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.